1912

Does short-term montelukast treatment cause sleep problems or psychiatric problems in children? A preliminary study

Aim: Montelukast is one of the treatment choices for symptomatic allergic rhinitis and asthma in children. Various researches emphasized that montelukast use causes neuropsychiatric side effects. The aim of this study was to investigate the effect of short-term montelukast use on children's sleep habits, and whether sleep-related problems and psychiatric problems may occur.Material and Methods: This prospective study was conducted with 30 children. Psychiatric disorders and symptoms, sleep habits, sleep-related problems were evaluated before the use of montelukast. All of these evaluations were repeated at 4th and 8th week of treatment. Psychiatric assessment was performed with the Schedule for Affective Disorders and Schizophrenia for School Age Children-Present and Lifetime Version – Turkish. Sleep habits, sleep-related problems were assessed using the Children Sleep Habits Questionnaire Short Form (CSHQ-S) and the Pediatric Sleep Questionnaire (PSQ).Results: According to the psychiatric assessment, no psychiatric disease or symptom was identified before treatment and at the 4th and 8th week of treatment. The CSHQ-S and PSQ responses were evaluated and there was no significant difference between results obtained before treatment and at the 4th and 8th weeks of treatment.Conclusion: The results revealed that short-term montelukast use is safe and do not cause changes sleep habits, sleep-related problems or psychiatric problems in children. Long-term follow-up studies with high numbers of participants are needed to test these results and evaluate the possible neuropsychiatric side effects of long-term montelukast use.

PDF

___

1. Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006;36:689–703.
2. Yilmaz O, Altintas D, Rondon C, Cingi C, Oghan F. Effectiveness of montelukast in pediatric patients with allergic rhinitis. Int J Pediatr Otorhinolaryngol 2013;77:1922-4.
3. Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology 2014;94:60-70.
4. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization. GA(2)LEN and AllerGen). Allergy 2008;63:8–160.
5. Bousquet J, Demoly P, Humbert M. Montelukast in guidelines and beyond. Adv Ther 2009;26:575–87.
6. Storms W, Michele TM, Knorr B, Noonan G, Shapiro G, Zhang J, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy 2001;31:77–87.
7. Haarman MG, van Hunsel F, de Vries TW. Adverse drug reactions of montelukast in children and adults. Pharmacol Res Perspect 2017;5:e00341.
8. US Food and Drug Administration: Transcript of Singulair presentation, FDA Pediatric Advisory Committee Meeting. https:/www.fda.govdownloads/ ScienceResearch/SpecialTopicsPediatricTherapeutics Research / UCM434618.pdf access date 20.11.2019
9. European Medicines Agency: Opinion of the paediatric committee on the acceptance of a modification of an agreed paediatric investigation plan. https:// www.ema.europa.eu/en/documents/pip-decision/ p/200/2009-european-medicines-agency-decision- 1-october-2009-acceptance-modification-agreedpaediatric_ en.pdf access date 20.11.2019
10. Perona AA, García-Sáiz M, Álvarez ES. Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase®. Drug Saf 2016;39:69-78.
11. Schumock GT, Stayner LT, Valuck RJ, Joo MJ, Gibbons RD, Lee TA. Risk of suicide attempt in asthmatic children and young adults prescribed leukotrienemodifying agents: a nested case-control study. J Allergy Clin Immunol 2012;130:368–75.
12. Ali MM, O'Brien CE, Cleves MA, Martin BC. Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested case‐control study. Pharmacoepidemiol Drug Saf 2015;24:435-45.
13. Wallerstedt SM, Brunlöf G, Sundström A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf 2009;18:858-64.
14. Aldea-Perona A, Fernandez-Quintana E, Garcia- Sanchez-Colomer M. Up-to-date of the neuropsychiatric events in relation with antileukotriens-agents in the spanish surveillance system. Basic Clin Pharmacol Toxicol 2011;109:32–40.
15. Marchand MS, Jonville-Béra AP, Autret-Leca E. Association française des centres régionaux de pharmacovigilance. [Psychiatric disorders associated with montelukast: data from the National Pharmacovigilance Database]. Arch Pediatr 2013;20:269–73.
16. Benard B, Bastien V, Vinet B, Yang R, Krajinovic M, Ducharme FM. Neuropsychiatric adverse drug reactions in children initiated on montelukast in reallife practice. Eur Respir J 2017;50:1700148.
17. Schneider HE, Lam JC, Mahone EM. Sleep disturbance and neuropsychological function in young children with ADHD. Child Neuropsychol 2016;22:493-506.
18. Del Giacco SR, Cappai A, Gambula L. The asthmaanxiety connection. Respir Med 2016;120:44-53.
19. Zandieh SO, Cespedes A, Ciarleglio A, Bourgeois W, Rapoport DM, Bruzzese JM. Asthma and subjective sleep disordered breathing in a large cohort of urban adolescents. J Asthma 2017;54:62-8.
20. Borschuk AP, Rodweller C, Salorio CF. The influence of comorbid asthma on the severity of symptoms in children with attention-deficit hyperactivity disorder. J Asthma 2018;55:66-72.
21. Kavanagh J, Jackson DJ, Kent BD. Sleep and asthma. Curr Opin Pulm Med 2018;24:569-73.
22. Bulcun E, Turkel Y, Oguztürk O. Psychological characteristics of patients with asthma. Clin Respir J 2018;12:113-8.
23. Kaufman J, Birmaher B, Brent D. Schedule for Affective Disorders and Schizophrenia for School-Age Children- Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980-8.
24. Gökler B, Ünal F, Pehlivantürk B, Çengel-Kültür E, Akdemir D, Taner Y. Okul Çağı Çocukları İçin Duygulanım Bozuklukları ve Şizofreni Görüşme Çizelgesi-Şimdi ve Yaşam Boyu Şekli-Türkçe Uyarlamasının Geçerlik ve Güvenirliği. [Reliability and validity of schedule for affective disorders and schizophrenia for school age children-present and lifetime version-Turkish version]. Turk J Child Adolesc Ment Health 2004;11:109-16.
25. Owens JA, Spirito A, McGuinn M. The Children’s Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school- aged children. Sleep 2000;15:1043-51.
26. Fis NP, Arman A, Ay P, Topuzoglu A, Güler AS; Gökçe İmren S, et al. Çocuk Uyku Alışkanlıkları Anketinin Türkçe geçerliliği ve güvenilirliği. [The validity and the reliability of Turkish Version of Children’s Sleep Habits Questionnaire]. Anatolian J Psychiatry 2010;11:151– 60.
27. Chervin RD, Hedger KM, Dillon JE, Pituch KJ. Pediatric Sleep Questionnaire (PSQ): validity and reliability of scales for sleep-disordered breathing, snoring, sleepiness, and behavioral problems. Sleep Med 2000;1:21-32.
28. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (DSM-IV). American Psychiatric Publishing, Washington, 2000.
29. Yüksel H, Söğüt A, Yılmaz O, Kutluay E. Reliability and validity of the Turkish version of the pediatric sleep questionnaire: a tool for prediction of sleep related breathing disorder. Tuberk Toraks 2011;59:236-41.
30. Bygdell M, Brunlöf G, Wallerstedt SM, Kindblom JM. Psychiatric adverse drug reactions reported during a 10-year period in the Swedish pediatric population. Pharmacoepidemiol Drug Saf 2012;21:79–86.
31. Goodwin RD, Bandiera FC, Steinberg D, Ortega AN, Feldman JM. Asthma and mental health among youth: etiology, current knowledge and future directions. Expert Rev Respir Med 2012;6:397–406.
32. Philip G, Hustad CM, Malice MP et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:699- 706.